BioSpace6d
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
The Motley Fool12d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.
FiercePharma7d
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
CNBC on MSN7d
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
NBC Washington7d
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...